Scholarlink

<p>While FDA-approved liposomal drugs (e.g., Doxil®) have demonstrated improved toxicity profiles and targeted delivery, emerging evidence reveals paradoxical pro-angiogenic and immunosuppressive effects that compromise therapeutic outcomes. This review examines the critical yet underappreciated role of complement system activation in mediating these adverse effects. We present a comprehensive analysis of the dynamic interactions between liposomal formulations, complement proteins, and the tumor microenvironment. By elucidating these mechanisms, we identify key challenges and opportunities for optimizing nanocarrier design. Our synthesis provides a framework for developing next-generation liposomal therapeutics with enhanced efficacy and reduced immunogenic potential, offering important insights for translational cancer nanomedicine.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Liposomes in tumor treatment: a double-edged sword

  • 期刊论文

  • 发表日期：

    2026年1月9日

查看全文
  • Guo Wu,
  • Haotian Li,
  • Yixia Liang,
  • Senlin Li,
  • Xiuling Li,
  • Phei Er Saw

摘要

While FDA-approved liposomal drugs (e.g., Doxil®) have demonstrated improved toxicity profiles and targeted delivery, emerging evidence reveals paradoxical pro-angiogenic and immunosuppressive effects that compromise therapeutic outcomes. This review examines the critical yet underappreciated role of complement system activation in mediating these adverse effects. We present a comprehensive analysis of the dynamic interactions between liposomal formulations, complement proteins, and the tumor microenvironment. By elucidating these mechanisms, we identify key challenges and opportunities for optimizing nanocarrier design. Our synthesis provides a framework for developing next-generation liposomal therapeutics with enhanced efficacy and reduced immunogenic potential, offering important insights for translational cancer nanomedicine.